- Home
- UVV vs VRDN Comparison
UVV vs VRDN Comparison
Compare UVV & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UVV
- VRDN
- Stock Information
- Founded
- UVV 1886
- VRDN 2006
- Country
- UVV United States
- VRDN United States
- Employees
- UVV N/A
- VRDN N/A
- Industry
- UVV Farming/Seeds/Milling
- VRDN Medical Specialities
- Sector
- UVV Industrials
- VRDN Health Care
- Exchange
- UVV Nasdaq
- VRDN Nasdaq
- Market Cap
- UVV 1.3B
- VRDN 1.6B
- IPO Year
- UVV N/A
- VRDN N/A
- Fundamental
- Price
- UVV $53.28
- VRDN $21.27
- Analyst Decision
- UVV
- VRDN Strong Buy
- Analyst Count
- UVV 0
- VRDN 10
- Target Price
- UVV N/A
- VRDN $36.33
- AVG Volume (30 Days)
- UVV 226.5K
- VRDN 718.1K
- Earning Date
- UVV 08-06-2025
- VRDN 11-11-2025
- Dividend Yield
- UVV 6.15%
- VRDN N/A
- EPS Growth
- UVV N/A
- VRDN N/A
- EPS
- UVV 4.11
- VRDN N/A
- Revenue
- UVV $2,943,996,000.00
- VRDN $305,000.00
- Revenue This Year
- UVV $1.52
- VRDN N/A
- Revenue Next Year
- UVV $0.97
- VRDN $34,044.63
- P/E Ratio
- UVV $12.98
- VRDN N/A
- Revenue Growth
- UVV 4.11
- VRDN 5.90
- 52 Week Low
- UVV $49.40
- VRDN $9.90
- 52 Week High
- UVV $67.33
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- UVV 38.54
- VRDN 56.26
- Support Level
- UVV $51.90
- VRDN $20.71
- Resistance Level
- UVV $53.38
- VRDN $22.37
- Average True Range (ATR)
- UVV 0.89
- VRDN 0.95
- MACD
- UVV -0.27
- VRDN -0.09
- Stochastic Oscillator
- UVV 25.55
- VRDN 62.26
About UVV Universal Corporation
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).